CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Cullinan Therapeutics, Inc. announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial. As of.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) fell 4.5% on Tuesday . The company traded as low as $22.99 and last traded at $23.05. 266,559 shares traded hands during trading, a decline of 58% from the average session volume of 630,100 shares. The stock had previously closed at $24.13. Wall Street Analysts Forecast Growth […]
HC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Viking, CRISPR, Cytokinetics are M&A targets: Wells Fargo seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.